Tremfya Leads TV Pharma Ads in September and Q3
Johnson & Johnson's Tremfya retained its top spot for TV pharma brand ad impressions in September, with a 5.02% impressions share of voice (SOV) and 3.1 billion impressions, following an ad spend of $32.8 million.
- Tremfya's ad spend increased by approximately $10 million compared to August.
- The psoriasis/ulcerative colitis drug garnered most impressions from Univision's ¡Despierta América!
Vicks took the runner-up title, knocking AbbVie's Skyrizi to third place, with a 4.71% impressions SOV and 2.9 billion impressions, primarily through CBS and its show GMA 3: What You Need to Know, after investing $10.3 million in TV ad spend.
The fall sports season and Spanish language TV played a significant role in delivering TV pharma ad impressions in September.
Author's summary: Tremfya leads TV pharma ads in September.